Sector & Market
AstraZeneca Shares Drop 1.6% After FDA Rejection
AstraZeneca's London-listed shares fell 1.6% after the FDA's Oncologic Drugs Advisory Committee voted 6‑3 against camizestrant.
The panel said camizestrant showed no meaningful benefit for patients wi
